Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AV2-SA2
- Development stage
- Unknown
- Lead developer
- Cesa Alliance
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**AV2-SA2** is an investigational topical combination regimen for **cutaneous warts** caused by human papillomavirus. It combines AV2, also called Omnivirol, a virucidal essential-oil mixture containing carvone, eugenol, geraniol, and nerolidol, with salicylic acid. AV2 is postulated to deactivate infectious HPV virions before cellular entry, while salicylic acid provides local keratolytic and ablative removal of wart tissue. The regimen was evaluated against salicylic acid alone in the randomized OVW-SA001 study. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S2451865420300181))
- Other names
- AV2 + salicylic acidAV2-SAAV-2-SAAV 2-SAOmnivirol-Salicylic acid combination therapy
Beyond the preview
Go deeper on AV2-SA2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AV2-SA2.